Health Stocks Comparison: Why GEHC Presents a Stronger Valuation Case Against SYK

For investors exploring opportunities within the health stocks sector, particularly among medical device and healthcare technology companies, the choice between GE HealthCare Technologies (GEHC) and Stryker (SYK) often comes down to one critical question: which offers genuine value at current price levels? Both companies operate in the competitive medical products space, but their financial profiles tell markedly different stories when examined through a rigorous valuation lens.

The foundation of any value investing strategy combines systematic ranking frameworks with traditional valuation metrics. Investment analysts at Zacks employ a dual-pronged approach: the Zacks Rank system, which identifies companies experiencing positive earnings momentum, paired with Style Score evaluations that assess stocks across multiple fundamental dimensions. Under this framework, GEHC currently earns a Zacks Rank of #2 (Buy), signaling stronger positive earnings estimate revisions compared to SYK’s #3 (Hold) ranking. This distinction matters significantly for health stocks investors monitoring earnings trajectory improvements.

Earnings Estimate Revisions: A Key Advantage for GEHC

The divergence in Zacks Rank between these two health stocks reflects a fundamental difference in analyst sentiment and earnings outlook. GEHC’s #2 ranking indicates that Wall Street has been revising earnings estimates upward more robustly than for SYK. For value-focused investors, this metric serves as a leading indicator—when companies see improving profit expectations, it often precedes valuation expansion. Conversely, SYK’s #3 holding pattern suggests more muted earnings momentum among health stocks in the medical device category, warranting a more cautious stance.

Valuation Metrics Reveal Significant Divergence

When examining health stocks through traditional valuation lenses, the quantitative evidence becomes even more compelling. The Price-to-Earnings (P/E) ratio remains the most widely tracked metric for assessing relative value. GEHC trades at a forward P/E of 15.89, substantially lower than SYK’s 24.22. This 53% valuation gap signals that investors are paying significantly more for each dollar of Stryker’s future earnings compared to GE HealthCare—a critical consideration for value-conscious investors sifting through health stocks.

The PEG (Price/Earnings to Growth) ratio provides additional nuance by factoring in expected earnings growth rates. Rather than comparing raw earnings multiples, PEG normalizes for growth expectations. GEHC’s PEG ratio stands at 1.75, while SYK registers 2.11. A lower PEG typically suggests more attractive valuation relative to growth prospects, further favoring the healthcare technology leader among these health stocks options.

Perhaps most revealing is the Price-to-Book (P/B) ratio comparison. This metric weighs market capitalization against book value (total assets minus liabilities), offering insight into how much investors pay for each dollar of net asset backing. GEHC’s P/B of 3.47 compares favorably to SYK’s 6.16—nearly double. For investors seeking health stocks with reasonable asset valuations, GEHC presents a measurably more disciplined entry point.

Investment Grade Assessment

Zacks’ comprehensive Value category grades stocks across the P/E ratio, P/S ratio, earnings yield, cash flow per share, and numerous other fundamental metrics. Synthesizing these dimensions, GEHC receives a Value grade of A, whereas SYK lands at C. These grades encapsulate the quantitative reality: among health stocks within the medical devices and healthcare technology sectors, GEHC exhibits substantially more attractive pricing relative to fundamental quality.

The Verdict for Health Stocks Investors

The analytical convergence is striking. GEHC demonstrates superior earnings momentum based on revision trends, commands significantly lower valuation multiples across three critical metrics, and earns a substantially higher investment grade. For investors specifically interested in health stocks offering genuine value characteristics rather than premium pricing, the evidence increasingly points toward GE HealthCare as the more compelling opportunity. While both companies operate in attractive healthcare markets, only one appears genuinely undervalued at current price levels.

Zacks’ research team continues monitoring both positions and has identified what they believe represents an even more compelling opportunity—one stock they view as positioned to “at least double.” Their Director of Research recently highlighted one recommendation they view as superior to their broader Top 5 list, suggesting that diligent investors focused on health stocks and value principles can uncover exceptional opportunities beyond these two comparisons.